Clinical data has the potential to transform the healthcare system and we are in the midst of a healthcare data revolution. However, health care data can be unique and difficult to measure. Aetion, the Real World Evidence Platform®, allows the healthcare industry to make critical decisions about treatments and drug development from a high-level and detailed perspective. Real World Evidence leads to informed decision-making and Aetion, founded by two physicians from Harvard, enables this with a focus on technology and big data. CEO Carolyn Magill shares more about how the company powers regulators, biopharma, payers, and health technology assessment (HTA) bodies, the company’s future plans, and Aetion’s Series B, which brings the total round size to $82B extension. Aetion has now raised a total of $93.6M across five rounds.
Most people have read about an exciting, “breakthrough” in medicine and only to discover a couple paragraphs later that the results are based upon a sample size of 30 people, but Aetion uses real-world data from sources that include insurance claims, electronic medical records, and patient-reported outcomes to enable healthcare organizations to make impactful, informed […]
The latest venture capital, seed, and angel deals for NYC startups for 2/5/19 featuring funding details for Aetion and Perksy.